DOI: https://doi.org/10.63345/ijrmp.v12.i9.1
Kritika Rathi
Independent Researcher
Gurugram, India
Abstract
This manuscript reviews the pharmacokinetics of cannabinoids and their emerging role in the treatment of neurological disorders. Cannabinoids, as bioactive compounds, have shown promising neuromodulatory, anti-inflammatory, and neuroprotective properties. This study synthesizes preclinical and clinical research up to 2021 to elucidate absorption, distribution, metabolism, and excretion profiles of various cannabinoids. In addition, it discusses the challenges of formulation, dosage standardization, and variability in patient responses, offering insights into future research directions. The outcomes indicate that while cannabinoids hold therapeutic potential, further controlled trials and mechanistic studies are essential for optimizing their use in neurological disease management.
Keywords
Cannabinoids; Pharmacokinetics; Neurological Disorders; Neuroprotection; Metabolism; Clinical Trials
References
- https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.mdpi.com%2F1422-0067%2F26%2F1%2F152&psig=AOvVaw2OusDZkPaCl6Y4cUCxcL6C&ust=1741702193199000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCJCMlrXY_4sDFQAAAAAdAAAAABAK
- https://www.google.com/url?sa=i&url=https%3A%2F%2Fwww.intechopen.com%2Fchapters%2F76045&psig=AOvVaw1RBPaf1eXOQ-q-0Uq33uNU&ust=1741702320670000&source=images&cd=vfe&opi=89978449&ved=0CBQQjRxqFwoTCPD-0vLY_4sDFQAAAAAdAAAAABAE
- Pertwee, R. G. (2006). Cannabinoid pharmacology: The first 66 years. British Journal of Pharmacology, 147(S1), S163–S171.
- Di Marzo, V. (2008). Targeting the endocannabinoid system: To enhance or reduce? Nature Reviews Drug Discovery, 7(5), 438–455.
- Mechoulam, R., & Parker, L. A. (2013). The endocannabinoid system and the brain. Annual Review of Psychology, 64, 21–47.
- Huestis, M. A. (2007). Human cannabinoid pharmacokinetics. Chemistry & Biodiversity, 4(8), 1770–1804.
- Zuardi, A. W. (2006). History of cannabis as a medicine: A review. Revista Brasileira de Psiquiatria, 28(2), 153–157.
- Iffland, K., & Grotenhermen, F. (2017). An update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. Cannabis and Cannabinoid Research, 2(1), 139–154.
- Zhornitsky, S., & Potvin, S. (2012). Cannabidiol in humans—the quest for therapeutic targets. Pharmaceuticals, 5(5), 529–552.
- Millar, S. A., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2018). A systematic review on the pharmacokinetics of cannabidiol in humans. Frontiers in Pharmacology, 9, 1365.
- Devinsky, O., Cross, J. H., Laux, L., Marsh, E., Miller, I., Nabbout, R., et al. (2017). Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. New England Journal of Medicine, 376(21), 2011–2020.
- McGuire, P., Robson, P., Cubala, W. J., Vasile, D., Morrison, P. D., Barron, R., et al. (2018). Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: A multicenter randomized controlled trial. American Journal of Psychiatry, 175(3), 225–231.
- Ashton, C. H. (2001). Pharmacology and effects of cannabis: A brief review. British Journal of Psychiatry, 178(2), 101–106.
- Grotenhermen, F. (2003). Pharmacokinetics and pharmacodynamics of cannabinoids. Clinical Pharmacokinetics, 42(4), 327–360.
- Bhattacharyya, S., Crippa, J. A., Allen, P., Martin-Santos, R., Borgwardt, S., Fusar-Poli, P., et al. (2012). Induction of psychotic symptoms by Δ9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry, 69(1), 27–36.
- Silvestri, C., & Di Marzo, V. (2013). The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metabolism, 17(4), 475–490.
- Russo, E. B. (2011). Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. British Journal of Pharmacology, 163(7), 1344–1364.
- Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L., Cone, E. J., & Barnes, A. J. (1992). Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Archives of General Psychiatry, 49(4), 312–319.
- Pertwee, R. G. (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol, and Δ9-tetrahydrocannabivarin. British Journal of Pharmacology, 153(2), 199–215.
- Bonn-Miller, M. O., Loflin, M. J., Thomas, B. F., Marcu, J. P., Hyke, T., & Vandrey, R. (2017). Labeling accuracy of cannabidiol extracts sold online. JAMA, 318(17), 1708–1709.
- Millar, S. A., Stone, N. L., Yates, A. S., & O’Sullivan, S. E. (2019). The pharmacokinetics of cannabinoids. Clinical Pharmacokinetics, 58(10), 1039–1058.
- Crippa, J. A., Hallak, J. E., Guimarães, F. S., & Zuardi, A. W. (2004). Therapeutic use of the cannabinoid receptor agonist delta-9-tetrahydrocannabinol in neuropsychiatric disorders: A review of clinical data. Journal of Clinical Psychiatry, 65(4), 47–55.